AVH
Director Trades
| Date | Director | Value |
|---|---|---|
| S. Crowe | $9,987 | |
| R. McNamara | $160,100 | |
| R. McNamara | $145,640 |
Company News
AVITA Medical to launch RECELL GO system in US burn centres following FDA approval
Wound care management specialist AVITA Medical (ASX: AVH) has obtained US Food and Drug Administration (FDA) approval for its RECELL GO skin restoration system. RECELL GO is a cell-harvesting device that utilises the regenerative properties of a patient’s own skin to treat thermal burn wounds and full-thickness skin defects. Chief executive officer Jim Corbett said […]
What are the ASX stocks vulnerable to a ‘short squeeze’?
Could the ASX become subject to the same trading shenanigans in the US which put a rocket up the share price of struggling video outlet operator GameStop and then the silver market. It’s certainly food for short … er, thought. This month shares in online travel agent Webjet (ASX: WEB) have climbed around 10% as […]
Avita Medical enrols first patients in studies evaluating RECELL system
Regenerative medicine company Avita Medical (ASX: AVH) has commenced what it calls a “pivotal trial” for the treatment of paediatric scald injuries, seeking to demonstrate that its RECELL treatment can safely and effectively increase the incidence of healing when compared to a standard wound dressing. The new study is Avita’s second in as many days after […]
AVITA Medical publishes favourable study results for its RECELL System
Regenerative medicine company AVITA Medical (ASX: AVH) has published “favourable” results from an open-label feasibility study of its RECELL Autologous Cell Harvesting Device for the treatment of diabetic foot ulcers (DFUs). AVITA Medical has positioned itself as an innovative technology developer, intending to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA’s device […]
AVITA Medical prepares to launch its regenerative burn treatment in the US
Just over a month since its burns treatment system was approved for FDA’s compassionate use Investigational Device Exemption (IDE) program, regenerative medicine company AVITA Medical (ASX: AVH) has received a further boost courtesy of the US regulator. The FDA approved AVITA’s Premarket Approval (PMA) application to market the RECELL Autologous Cell Harvesting Device (RECELL System) […]
AVITA Medical receives FDA boost for compassionate use of RECELL device
Medical device maker AVITA Medical (ASX: AVH) has received good news this morning after the US Food and Drug Administration (FDA) said it had approved a program that could use more of its devices. The FDA approved a significant increase in the number of patients who may be treated using the “RECELL Autologous Cell Harvesting […]
Avita Medical grafts towards next generation of skin regeneration
Skin regeneration is on course for an overhaul on the back of revelations made by regenerative medicine company Avita Medical (ASX: AVH) with a technology platform able to treat severe burns. RECELL is a medical device designed to facilitate skin regeneration while minimising the amount of skin that must be “harvested” at the time of […]
Regenerative commercial potential on the horizon for Avita Medical
A new and potentially cost-saving method of treating second-degree burns developed by Avita Medical (ASX: AVH) is now undergoing a clinical trial in China. Avita hopes to see its RECELL treatment receive strong laboratory support following excellent testimonials and feedback received as a result of work done with Huddersfield University in the UK, as well […]
Avita Medical gets FDA approval for ReCell skin regeneration device supplement
Avita Medical (ASX: AVH) has gained FDA approval for a new continued access protocol for its ReCell autologous cell harvesting device, which simplifies a previously approved protocol for treating burn injuries. This essentially allows doctors to access the ReCell device while the premarket application is pending FDA approvals. ReCell works by taking a sample of […]
Company Videos
No videos found.